An association of NAG levels and a mutation of the CCK gene in panic disorder patients

Psychiatry Research

Volumn 80, Issue 2, 1998, Pages 149-153

  Garvey, Michael J ^a,b   Crowe, Raymond R ^b   Wang, Zhewu ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Cholecystokinin 4; Genetics; N acetyl glucosaminidase; Panic disorder

Indexed keywords

ACETYLGLUCOSAMINIDASE; TETRAGASTRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALE; MENTAL DISEASE; NEUROTRANSMISSION; PANIC; PRIORITY JOURNAL; RECEPTOR GENE;

ACETYLGLUCOSAMINIDASE; ADULT; CHOLECYSTOKININ; HUMANS; MUTATION; PANIC DISORDER;

EID: 0032541267     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(98)00063-8     Document Type: Article

References (42)

1. Alderman, M.H., Melcher, L., Drayer, D.E., Reidenberg, M.M., 1983. Increased excretion of N-acetyl-beta-glucosaminidase in essential hypertension and its decline with antihypertensive therapy. New England Journal of Medicine 309, 1213-1217.
2. Ballenger, J.C., Burrows, G.D., Du Pont, R.L., Jr., Lesser, I.M., Noyes, R., Jr., Pecknold, J.C., Rifkin, A., Swinson, R.P., 1988. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Archives of General Psychiatry 45, 413-422.
3. Bickerdike, M.J., Marsden, C.A., Dourish, C.T., Fletcher, A., 1994. The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze. European Journal of Pharmacology 271, 403-411.
4. Bradwejn, J., Koszycki, D., 1994. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. American Journal of Psychiatry 151, 261-263.
5. Bradwejn, J., Koszycki, D., Annable, L., Couetoux du Tertre, A., Reines, S., Karkanias, C., 1992a. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetra-peptide in panic disorder. Biological Psychiatry 32, 903-912.
6. Bradwejn, J., Koszycki, D., Bourin, M., 1991a. Dose ranging study of the effects of cholecystokinin in healthy volunteers. Journal of Psychiatry and Neuroscience 16, 91-95.
7. Bradwejn, J., Koszycki, D., Payeur, R., Bourin, M., Borthwick, H., 1992b. Replication of action of cholecystokinin tetrapeptide in panic disorder: clinical and behavioral findings. American Journal of Psychiatry 149, 962-964.
8. Bradwejn, J., Koszycki, D., Shriqui, C., 1991b. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Archives of General Psychiatry 48, 603-610.
9. Burry, H.C., Dieppe, P.A., Bresnihan, F.B., Brown, C., 1976. Salicylates and renal function in rheumatoid arthritis. British Medical Journal 1, 613-615.
10. Charney, D.S., Woods, S.W., Goodman, W.K., Heninger, G.R., 1987. Serotonin function in anxiety: II. Effects of the serotonin agonist mCPP in panic disorder patients and healthy controls. Psychopharmacology 92, 14-24.
11. Charney, D.S., Woods, S.W., Krystal, J.H., Nagy, L.M., Heninger, G.R., 1990. Hypothesis relating serotonergic dysfunction to the etiology and treatment of panic and generalized anxiety disorders. In: Coccaro, E.F., Murphy, D.L. (Eds.), Serotonin in Major Psychiatric Disorders. Progress in Psychiatry No. 21. American Psychiatric Press, Washington, DC, pp. 129-152.
12. de Montigny, C., 1989. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Archives of General Psychiatry 46, 511-517.
13. Dubach, A.C., Schmidt, A., 1979. Diagnostic Significance of Enzymes and Protein in Urine. Hans Huber Publishers, Bern, Stuttgart, Vienna.
14. Garvey, M.J., Furlong, C., Schaffer, C.B., Adelman, R., 1988. Elevation of the renal enzyme N-acetyl-beta-glucosaminidase in affective disorders and chemical dependence. Acta Psychiatrica Scandinavica 77, 247-252.
15. Garvey, M.J., Noyes, R., Jr., 1996. Association of levels of N-acetyl-beta-glucosaminidase with severity of psychiatric symptoms in panic disorder. Psychiatry Research 60, 185-190.
16. Garvey, M., Noyes, R.J., Cook, B., Barrickman, L., Noel, M., Ghosheh, R., 1990. Elevated levels of N-acetyl-beta-glucosaminidase in affective disorders and chemical dependence. Journal of Affective Disorders 19, 279-285.
17. Garvey, M.J., Noyes, R.J., Woodman, C., Laukes, C., 1993. A biological difference between panic disorder and general anxiety disorder. Biological Psychiatry 34, 572-575.
18. Garvey, M.J., Tuason, V.B., Blomquist, C.H., Hwang, S., 1982. Use of renal enzymes to evaluate nephrotoxicity in lithium treated patients. British Journal of Psychiatry 141, 420-422.
19. Kahn, R.S., Kalus, O., Wetzler, S., van Praag, H., 1991. The Role of Serotonin in the Regulation of Anxiety. Brunner/Mazel, New York.
20. Kahn, R.S., Wetzler, S., van Praag, H., Asnis, G.M., Strauman, T., 1988. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Research 25, 101-104.
21. Kathol, R.G., Noyes, R.J., Lopez, A.L., Reich, J., 1988. Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Research 24, 211-221.
22. Kunin, C.M., Chesney, R.W., Craig, W.A., England, A.C., DeAngelis, C., 1978. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase in the general population. Pediatrics 62, 751-760.
23. Lydiard, R.B., Ballenger, J.C., Laraia, M.T., Fossey, M.D., Beinfeld, M.C., 1992. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. American Journal of Psychiatry 149, 691-693.
24. Mansell, M.A., Jones, N.F., Ziroyannis, P.N., Marson, W.S., 1978. N-acetyl-beta-glucosaminidase: a new approach to screening hypertensive patients for renal disease. Lancet 2, 803-805.
25. Maruhn, D., 1979. Evaluation of urinary enzyme patterns in patients with kidney disease and primary benign hypertension. Current Problems in Clinical Biochemistry 9, 135-149.
26. A receptors. British Journal of Clinical Pharmacology 100 suppl, p. 349.
27. Price, R.G., 1982. Urinary enzymes, nephrotoxicity, and renal disease. Toxicology 23, 99-135.
28. Price, R.G., Dance, N., Richard, B., Catell, W.R., 1970. The excretion of N-acetyl-beta-glucosaminidase and beta-galactosidase following surgery to the kidney. Clinica Chimica Acta 27, 65-72.
29. Raiteri, M., Paudice, P., Vallebuona, F., 1993. Release of cholecystokinin in the central nervous system [see comments]. Neurochemistry International 22, 519-527.
30. Reglero, A., Carretero, I., Cabezas, J.A., 1980. Increased serum alpha-L-fuctosidase and beta-N-acetylglucosaminidase activities in diabetic, cirrhotic, and gastric cancer patients. Clinica Chimica Acta 103, 155-158.
31. Rex, A., Fink, H., Marsden, C.A., 1994. Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze. Neuropharmacology 33, 559-565.
32. Rex, A., Marsden, C.A., Fink, H., 1997. Cortical 5-HT-CCK interactions and anxiety-related behaviour of guinea-pigs: a microdialysis study. Neuroscience Letters 228, 79-82.
33. Spitzer, R.L., Williams, B.W., 1982. Structured Clinical Interview for DSM-III. Biometrics Research Department, New York State Psychiatric Institute, New York.
34. Tucker, S.M., Boyd, P., Thompson, A.E., Price, R.G., 1975. Automated assay of N-acetyl-beta-glucosaminidase in a normal pathological human urine. Clinica Chimica Acta 62, 333-339.
35. Tucker, S.M., Pierce, R.J., Price, R.G., 1980. Characterization of human N-acetyl-β-glucosaminidase isoenzymes as an indicator of tissue damage in disease. Clinica Chimica Acta 102, 29-40.
36. van Megen, H.J., Westenberg, H.G., den Boer, J.A., Kahn, R.S., 1996. Cholecystokinin in anxiety. European Neuropsychopharmacology 6, 263-280.
37. van Megen, H.J., Westenberg, H.G., den Boer, J.A., Slaap, B., Scheepmakers, A., 1997. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology 129, 357-364.
38. Vasar, E., Peuranen, E., Oopik, T., Harro, J., Mannisto, P.T., 1993. Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze. Psychopharmacology 110, 213-218.
39. Wang, Z., Valdes, J., Noyes, R., Zoega, T., Crowe, R.R., 1998. Possible association of a cholecystokinin promoter polymorphism (CCK-36C-> T) with panic disorder. American Journal of Medical Genetics 81, 228-234.
40. Wellwood, J.M., Price, R.G., Ellis, B.G., Thompson, A.E., 1976. A note on the practical aspects of the N-acetyl-beta-glucosaminidase in human urine. Clinica Chimica Acta 69, 85-91.
41. Whiting, P.H., Ross, I.S., Borthwick, L., 1979. Serum and urine N-acetyl-beta-glucosaminidase in diabetics on diagnosis and subsequent treatment, and stable insulin dependent diabetics. Clinica Chimica Acta 92, 459-463.
42. Wollen, J.W., Turner, P., 1965. Plasma N-acteyl-beta-glucosaminidase and beta-glucuronidase in health and disease. Clinica Chimica Acta 12, 671-683.